The problem is that the profit making side of the business is becoming dominant. There will always be room for experimental procedures even if the US saw regulation that limited the profit-making abilities of health insurers.
The situation at the moment is that routine, basic medicine is being denied, often algorithmically, along with "pharmabro" types buying up basic medications for the sole purpose of increasing its price. That's starkly different from the development of novel medications demanding high prices to reward R&D efforts.
The situation at the moment is that routine, basic medicine is being denied, often algorithmically, along with "pharmabro" types buying up basic medications for the sole purpose of increasing its price. That's starkly different from the development of novel medications demanding high prices to reward R&D efforts.